Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Comparison of FDA accelerated vs regular pathway approvals for lung cancer treatments between 2006 and 2018

PLoS ONE(2020)10.1371/journal.pone.0236345Source: DataRank Database

Comparison of FDA accelerated vs regular pathway approvals for lung cancer treatments between 2006 and 2018 is a research paper published in PLoS ONE (2020). On theSindex it has a DataRank of 0. It has been cited 19 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access19 citations

Download PDF

Cite:

Linked data & code

doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (2 grants)Impact (FWCI 3.21)OA: goldTopics (58)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (4)

Lewis Buss ORCID,C. Wayant ORCID,Moacyr Roberto Cucê Nobre ORCID,Tatiane Bomfim Ribeiro ORCID

Live enrichment

PubMed:32706800 PMC:PMC7380631 OpenAlex:https://openalex.org/W3044069777

NCI NIH HHS

Grant: F30 CA243651

National Institutes of Health

Grant: 5F30CA243651-02

Evidence-based, systematic investigation of patient-reported outcome measures for positive psychosocial constructs in young patients with cancer.

FWCI

3.21

Citation Percentile

0.9%

Citation Trend

2021

2022

2023

2024

2025

goldLicense: cc-by

journalhttps://doi.org/10.1371/journal.pone.0236345

publisherhttps://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0236345&type=printable

publisherhttps://dx.plos.org/10.1371/journal.pone.0236345

repositoryhttps://pubmed.ncbi.nlm.nih.gov/32706800

repositoryhttps://doaj.org/article/56e89516d709450cb0089d0899db15f3

Fields of Study

Statistical Methods in Clinical TrialsHealth Systems, Economic Evaluations, Quality of LifeCancer Genomics and Diagnostics03 medical and health sciences0302 clinical medicineAntineoplastic AgentsDatabases, PharmaceuticalDrug ApprovalHumansLung NeoplasmsMarketingOutcome Assessment, Health CareResearch DesignSample SizeUncertaintyUnited StatesUnited States Food and Drug Administration

MeSH Terms

Antineoplastic AgentsHumansLung NeoplasmsResearch DesignUnited StatesUnited States Food and Drug AdministrationOutcome Assessment, Health CareDrug ApprovalSample SizeUncertaintyMarketingDatabases, Pharmaceutical

Keywords

MedicineSurrogate endpointSample size determinationFood and drug administrationLung cancerClinical endpointCancer drugsCancerOncologyInternal medicinePharmacologyClinical trialStatisticsMarketingLung NeoplasmsDatabases, PharmaceuticalUnited States Food and Drug AdministrationScienceQRUncertaintyAntineoplastic AgentsUnited StatesResearch DesignSample SizeOutcome Assessment, Health CareHumansDrug ApprovalResearch Article

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being

Comparison of FDA accelerated vs regular pathway approvals for lung cancer treatments between 2006 and 2018

FAIR Checklist

Authors (4)

Funding (2 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)